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Abstract 
Vancomycin is an important nosocomial antibiotic containing a glycosylated, cross-
linked and doubly chlorinated heptapeptide backbone. During the biosynthesis of the 
vancomycin aglycone, two ß-hydroxytyrosine (Bht) residues are inserted at positions-
2 and -6 into the heptapeptide backbone by a non-ribosomal peptide synthetase. A 
single flavin-dependent chlorinase (VhaA) is responsible for chlorinating both Bht 
residues at some ill-defined point in the assembly process. We show here using in 
vitro assays that VhaA is able to introduce a chlorine atom into each aromatic ring of 
both Bht residues at positions-2 and -6 of a peptide carrier protein-bound hexapeptide. 
The results suggest that VhaA can recognize and chlorinate two quite different sites 
within a linear hexapeptide intermediate during vancomycin biosynthesis. 
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Vancomycin and related glycopeptides are important antibiotics of last-resort used in 
hospitals to treat infections caused by multi-drug resistant (MDR) Gram-positive 
bacteria. Unfortunately, bacterial resistance to the glycopeptides is also growing 
relentlessly, and this is fuelling efforts to discover new glycopeptides able to combat 
these MDR bacteria.1 Several promising semi-synthetic derivatives are already in 
clinical development, including oritavancin, dalbavancin and telavancin.2 Apart from 
semi-synthesis, novel glycopeptides have also been made by exploiting the 
biosynthetic machinery responsible for assembling these complex natural products, 
including derivatives with novel halogenation or glycosylation patterns.3-5 However, 
further progress is currently hampered by the incomplete state of knowledge of 
vancomycin biosynthesis.6,7 
 The cross-linked and halogenated heptapeptide backbone is important for the 
antimicrobial activity of vancomycin-type antibiotics (Figure 1).8,9 The peptide 
backbone is assembled by a non-ribosomal peptide synthetase (NRPS) comprising 3 
subunits (VpsA/B/C), containing altogether 7 modules (M) (VpsA (M1-3), VpsB 
(M4-6) and VpsC (M7)), each with a domain for activation (A) and six with a domain 
for coupling (C) activated amino acids into the growing peptide chain (Figure 1).3,10 
The C-O-D cross-link is installed by the P450 enzyme OxyB on a linear hexapeptide 
intermediate linked as a thioester to the peptide carrier protein (PCP) domain in 
module 6 at the C-terminus of VpsB.11-13 The remaining two cross-linking steps, 
catalyzed in-turn by OxyA and OxyC also likely occur on NRPS-bound 
intermediates,14-16 although this has so far not been shown with in vitro assays. Many 
glycopeptides, including vancomycin, balhimycin and chloroeremomycin, contain 
chlorine substituents in the aromatic side chains of residues-2 and -6 in the aglycone. 
The chlorine substituents improve binding affinity to the D-Ala-D-Ala target in vitro 
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and antimicrobial activity against Staphylococcus aureus.17-19 The timing of the 
halogenation steps during vancomycin-type glycopeptide biosynthesis, however, has 
so far not been determined. The biosynthetic gene clusters of vancomycin, balhimycin 
and chloroeremomycin include a single halogenase, which is responsible for 
introducing both chlorine substituents.3 Inactivation of the halogenase gene in the 
balhimycin producer (∆bhaA) leads to the production of dechlorobalhimycin.20 Also, 
supplementing mutants blocked in ß-hydroxytyrosine (Bht) biosynthesis (∆oxyD and 
∆bpsD) with free Bht, restored production of the dihalogenated antibiotic, whereas 
chloro-ß-hydroxytyrosine (Cht) was not accepted by these mutants, implying that Cht 
is not a free biosynthetic intermediate and is not accepted as a substrate by the 
NRPS.21 These results suggest that chlorination occurs after activation of Bht, 
possibly after incorporation into the growing peptide chain, on peptide intermediates 
linked as thioesters to PCP domains of the NRPS. In this work, we report the first 
detection of in vitro activity from the vancomycin halogenase, in assays with 
synthetic peptide-PCP conjugates. 
 The halogenase used for these studies (VhaA) was from the vancomycin 
producer Amycolatopsis orientalis DSM40040 (see Supporting Information). VhaA 
was produced as a soluble protein with an N-terminal hexa-histidine tag in 
Escherichia coli BL21(DE3)pLysS, and was purified to apparent homogeneity by 
SDS-PAGE after Ni-affinity chromatography, anion-exchange on MonoQ and gel-
filtration chromatography. The protein is yellow in color with peaks at 375 and 450 
nm in the UV-Vis spectrum, characteristic of a flavoprotein. Denaturation of the 
protein led to release of the flavin cofactor, which migrated on TLC like authentic 
FAD, but not FMN (see Supporting Information). However, extended dialysis of 
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native VhaA (Tris-HCl buffer, pH 7.5) did not lead to loss of yellow color, indicating 
that the FAD is tightly bound to the protein. 
 Known FAD-dependent halogenases involved in natural product biosynthesis 
typically require an NAD(P)H-dependent flavin reductase to generate reduced flavin 
(FADH2) for halogenation.22-24 However, no gene encoding a flavin reductase has so 
far been found within a biosynthetic gene cluster for vancomycin-like glycopeptides, 
so we investigated a strategy used successfully elsewhere, where the heterologous 
flavin reductase SsuE from E. coli is used to supply reducing equivalents from 
NADPH to the halogenase.22,23 This soluble flavin reductase was produced in E. coli 
with an N-terminal His6-tag and purified to homogeneity. When SsuE was added to 
aqueous buffer containing just free FAD and NADPH, the yellow color of the flavin 
was rapidly lost due to formation of colorless FADH2, but the yellow color re-
appeared very rapidly when NADPH had been consumed due to re-oxidation of the 
flavin by molecular oxygen. When SsuE is added to buffer containing VhaA and 
NADPH, the halogenase-bound flavin was rapidly reduced (reduced absorption at 450 
nm), but again upon exhaustion of NADPH the yellow color returned within ca. 2 min 
(see Supporting Information). These experiments show that the flavin reductase SsuE 
can reduce the halogenase VhaA, but also that the reduced flavin is rapidly re-
oxidized under the aerobic conditions needed for halogenation. 
 We first examined the dipeptide 1 as a potential substrate for VhaA (Scheme 
1). This dipeptide corresponds to the product expected after the first coupling reaction 
on the NRPS (VpsA), except that it is linked to a peptide carrier protein (PCP) 
domain derived from module-7 (called PCP7) and contains a methylated N-terminus. 
The production and favorable folding and stability of PCP7 were reported earlier 
during in vitro studies with the cross-linking enzyme OxyB.25 The dipeptide 1 was 
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incubated with VhaA, SsuE, NADPH and NaCl as chloride source, and after 60 min 
the reaction was stopped by addition of hydrazine to release the dipeptide from the 
PCP as an acyl-hydrazide. The peptidic products were extracted and analyzed by 
HPLC and mass spectrometry. Despite repeated attempts, however, no chlorinated 
dipeptide hydrazide could be detected in these assays, showing that 1 is not a suitable 
substrate for the halogenase. 
 We next turned to the hexapeptide-PCP7 conjugate 2 as a potential substrate 
(Scheme 1). HPLC chromatograms of the product mixture extracted after the assay 
with VhaA and SsuE, and work-up with hydrazine, now revealed a new peak with a 
mass corresponding to that of the bis-chlorinated product 3 (high resolution 
electrospray MS (HR-ESI-MS) m/z (observed) 998.3210 [M+H]+; m/z (calculated) 
998.3213). The observed and simulated HR-ESI-MS for the isolated 3 (Figure 2) 
show the characteristic isotopic pattern for a doubly chlorinated product. The yield of 
this product was rather low, corresponding to a turn-over of only 10-15% of the 
available substrate into bis-chlorinated product. The chlorinated hexapeptide 3 was 
also prepared synthetically by reacting the corresponding chlorinated hexapeptide 4 
(described in earlier work25) with hydrazine. This synthetic 3 was indistinguishable by 
HPLC and HR-ESI-MS from that derived from the halogenase assay (see Supporting 
Information). In order to confirm the expected positions of chlorination in 3 from the 
assay, the peptide was analyzed by ESI-MS/MS. The identified fragment ions confirm 
the presence of Cht at positions-2 and -6 in the hexapeptide backbone (Supporting 
Information). Interestingly, a careful analysis of the products from the assay revealed 
non-chlorinated linear hexapeptide 3a and various degradation products arising from 
3a by elimination of water or retro-aldol reactions, but no mono-chlorinated peptide 
could be detected, suggesting an efficient processing of the substrate into the bis-
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chlorinated product. When VhaA or SsuE were absent in the assay, no chlorinated 
product was observed. Moreover, when the halogenase assay was repeated using as 
substrate the simplified model hexapeptide 2a (Scheme 1),11-13 containing tyrosine in 
place of Bht at positions-2 and -6, no chlorinated product was detected, showing that 
2a is not a good substrate for VhaA under these in vitro conditions. We also coupled 
the hexapeptide to an engineered PCP domain derived from module-6 (PCP6) of 
VpsB, the natural partner for the hexapeptide intermediate during vancomycin 
assembly (Figure 1). However, in assays with VhaA we could not detect formation of 
any halogenated peptide(s). This PCP6 domain was shown in earlier work to be less 
stable in buffer than the excised PCP7,11,25 suggesting that the efficiency of substrate 
conversion by VhaA may be influenced by the folding properties and/or stability of 
the PCP domain when engineered-out of this multidomain NRPS. The low turnover 
observed in the assays with 2 might partly reflect a low intrinsic catalytic efficiency 
of VhaA, as found for several other biosynthetic FADH2-dependent 
halogenases,23,24,26-29 as well as the non-ideal in vitro assay conditions employed here 
(vide supra). We have also attempted coupled assays with substrate 2 and the P450 
enzyme OxyB and VhaA together, but no halogenated products were detected (results 
not shown), most likely due to the complexity of the assay cocktail and mixture of 
ancillary redox proteins required to drive both enzymes. 
 The timing of chlorination during vancomycin biosynthesis has been 
addressed so far using molecular genetic approaches on balhimycin biosynthesis. For 
example, blocked mutants of Bht biosynthesis (∆dpgA and ∆bpsC) produced 
chlorinated linear N-terminal di-, tri-, tetra- and penta-peptides as well as a bis-
chlorinated linear hexapeptide. Since it could not be ruled out that the shorter peptides 
might be derived by proteolytic degradation of the hexapeptide over the course of a 
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long whole-cell fermentation, the timing of chlorination remained unresolved.13 In 
another study, oxyA and oxyC mutants produced singly or doubly cross-linked 
products, respectively, that were fully chlorinated, whereas an oxyB mutant gave only 
non-chlorinated linear hexa- and heptapeptide products. This intriguing observation 
suggests a close link between the site(s) or timing of the steps catalyzed by the 
halogenase and the cross-linking enzyme OxyB.30 It would now be of great interest to 
test whether a synthetically derived hexapeptide-PCP already containing the C-O-D 
cross-link, as well as a variety of other linear peptide-PCP conjugates, act as 
substrates for VhaA. More detailed studies of the entire module-6 from the NRPS 
would also be of great interest, including its structure with bound hexapeptide, and 
mode of interaction with VhaA and OxyB. 
 
Conclusions 
 We report here for the first time in vitro activity for the halogenase involved in 
the biosynthesis of vancomycin-like glycopeptide antibiotics, and demonstrate the 
remarkable ability of the enzyme to chlorinate two quite different sites within the 
hexapeptide-PCP substrate 2. The results highlight the critical role played by the 
linear hexapeptide intermediate during vancomycin assembly as it arrives on the PCP 
domain in module-6 of the NRPS (Figure 1). Here two important modifications may 
occur; halogenation catalyzed by VhaA and cross-linking by OxyB. The results 
provide a starting point for more detailed in vitro studies on the timing of these two 
tailoring steps during vancomycin assembly, as well as more detailed structural 
studies on module 6 of the vancomycin NRPS. 
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Figures and Schemes 
Figure 1. Vancomycin backbone assembly on the NRPS, and the structure of 
vancomycin. Individual domains of the NRPS are depicted (C=condensation domain; 
A=activation domain; TE=thioesterase domain; X=domain of unknown function; 
PCP=peptide carrier protein domain) (see text). The sites of cross-linking by OxyB 
and chlorination in the hexapeptide-PCP intermediate are indicated. 
 
Figure 2. A, Analytical HPLC chromatogram of products isolated after hydrazine 
work-up from in vitro assays with VhaA and hexapeptide-PCP7 substrate 2. Peak 1, 
m/z 930.4 [M+H]+, residual non-chlorinated hexapeptide hydrazide (3a); peak 2, m/z 
998.3 [M+H]+, dichlorinated hexapeptide hydrazide 3. B, High resolution ESI-MS 
spectrum showing the quasi-molecular ion [M+H]+ (m/z) and isotopic pattern 
observed for 3 generated in the assay (top) and the simulated spectrum for the 
dichlorinated molecular formula C45H54Cl2N9O13 (below) (see Supporting Information 
for the complete spectrum). 
 
Scheme 1. Synthetic peptides used in this work.11,25 For experimental details of the 
assays see Supporting Information. 
 
 
 
 
 13 
Graphical and textual abstract 
The vancomycin biosynthetic halogenase can bis-chlorinate both ß-hydroxytyrosine 
residues-2 and -6 in a model substrate comprising a PCP-linked hexapeptide. 
 
 
